Products
Forimtamig Biosimilar Bispecific Antibody (GPRC5D × CD3) for Research
Cat No.: GMP-Bios-INN-1207
Anti-GPRC5D therapeutic antibody (Pre-made Forimtamig biosimilar,Bispecific mAb with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Forimtamig (development code RG6234) is a bispecific antibody targeting GPRC5D and CD3. It is developed by Roche for multiple myeloma and other hematological malignancies. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1207-1mg | 1mg | |
| GMP-Bios-INN-1207-10mg | 10mg | |
| GMP-Bios-INN-1207-100mg | 100mg | |
| GMP-Bios-INN-1207-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Forimtamig biosimilar, Bispecific mAb with Domain Crossover, Anti-GPRC5D;CD3E Antibody: Anti-GPRC5D/G-protein coupled receptor family C group 5 member D/T3E/TCRE therapeutic antibody |
| INN Name | Forimtamig |
| Target | GPRC5D;CD3E |
| Format | Bispecific mAb with Domain Crossover |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Multiple myeloma |
| Production | na |
| Development Tech | na |
